News BMS strikes three-year cancer R&D deal with Flatiron Bristol-Myers Squibb has struck a three-year with Flatiron Health that aims to make cancer R&D more efficient and patient-focused.
News Pfizer might buy BMS for $130bn – but should it? Pfizer could soon launch a multi-billion dollar bid for immunotherapy rivals Bristol-Myers Squibb.
R&D Reuters Pharma USA 2024 – Meruno Perugini Innovation in pharma comes in many forms, but at the end of the day what the industry cares about is results.
Digital Fixing clinical trial data management It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.